[1] ZURA R, XIONG Z, EINHORN T, et al. Epidemiology of Fracture Nonunion in 18 Human Bones. JAMA Surg. 2016;151(11):e162775.
[2] ROCHA-RODRIGUES S, RODRÍGUEZ A, GOUVEIA AM, et al. Effects of physical exercise on myokines expression and brown adipose-like phenotype modulation in rats fed a high-fat diet. Life Sci. 2016;165:100-108.
[3] PAJARINEN J, LIN T, GIBON E, et al. Mesenchymal stem cell-macrophage crosstalk and bone healing. Biomaterials. 2019;196:80-89.
[4] ZHAO L, CHEN S, YANG P, et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019;10(1):182.
[5] BROWN C, MCKEE C, BAKSHI S, et al. Mesenchymal stem cells: Cell therapy and regeneration potential. J Tissue Eng Regen Med. 2019;13(9):1738-1755.
[6] VERONESI F, SALAMANNA F, TSCHON M, et al. Mesenchymal stem cells for tendon healing: what is on the horizon? J Tissue Eng Regen Med. 2017; 11(11):3202-3219.
[7] GRAFE I, ALEXANDER S, PETERSON JR, et al. TGF-β Family Signaling in Mesenchymal Differentiation. Cold Spring Harb Perspect Biol. 2018;10(5): a022202.
[8] Melnik S, Gabler J, Dreher SI, et al. MiR-218 affects hypertrophic differentiation of human mesenchymal stromal cells during chondrogenesis via targeting RUNX2, MEF2C, and COL10A1. Stem Cell Res Ther. 2020;11(1): 532.
[9] Pierce JL, Begun DL, Westendorf JJ, et al. Defining osteoblast and adipocyte lineages in the bone marrow. Bone. 2019;118:2-7.
[10] CASE N, RUBIN J. Beta-catenin--a supporting role in the skeleton. J Cell Biochem. 2010;110(3):545-553.
[11] LITTLE RD, CARULLI JP, DEL MASTRO RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70(1):11-19.
[12] CHEN J, LONG F. β-catenin promotes bone formation and suppresses bone resorption in postnatal growing mice. J Bone Miner Res. 2013;28(5):1160-1169.
[13] TAKAHASHI N, MAEDA K, ISHIHARA A, et al. Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. Front Biosci (Landmark Ed). 2011;16:21-30.
[14] NIE B, ZHOU S, FANG X, et al. Implication of receptor activator of NF-κB ligand in Wnt/β-catenin pathway promoting osteoblast-like cell differentiation. J Huazhong Univ Sci Technolog Med Sci. 2012;32(6):818-822.
[15] CHEN D, ZHAO M, MUNDY GR. Bone morphogenetic proteins. Growth Factors. 2004;22(4):233-241.
[16] ZHAO M, QIAO M, HARRIS SE, et al. The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Mol Cell Biol. 2006;26(16):6197-6208.
[17] AGHALOO T, COWAN CM, CHOU YF, et al. Nell-1-induced bone regeneration in calvarial defects. Am J Pathol. 2006;169(3):903-915.
[18] XIAN L, WU X, PANG L, et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med. 2012;18(7):1095-1101.
[19] KUROZUMI A, NAKANO K, YAMAGATA K, et al. IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2. Bone. 2019;124:53-61.
[20] FUKUYO S, YAMAOKA K, SONOMOTO K, et al. IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent. Rheumatology (Oxford). 2014;53(7):1282-1290.
[21] MAO Q, LIANG XL, WU YF, et al. ILK promotes survival and self-renewal of hypoxic MSCs via the activation of lncTCF7-Wnt pathway induced by IL-6/STAT3 signaling. Gene Ther. 2019;26(5):165-176.
[22] FAJGENBAUM DC, LANGAN RA, JAPP AS, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019;129(10):4451-4463.
[23] BAKKER AD, JASPERS RT. IL-6 and IGF-1 Signaling Within and Between Muscle and Bone: How Important is the mTOR Pathway for Bone Metabolism? Curr Osteoporos Rep. 2015;13(3):131-139.
[24] KAUR M, NAGPAL M, SINGH M. Osteoblast-n-Osteoclast: Making Headway to Osteoporosis Treatment. Curr Drug Targets. 2020;21(16):1640-1651.
[25] MARUOTTI N, CORRADO A, NEVE A, et al. Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol. 2012;68(7):1013-1018.
[26] NEVE A, CORRADO A, CANTATORE FP. Osteoblast physiology in normal and pathological conditions. Cell Tissue Res. 2011;343(2):289-302.
[27] YOUSIF AS, RONSARD L, SHAH P, et al. The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells. Immunity. 2021;54(2):235-246.e5.
[28] BARAN P, HANSEN S, WAETZIG GH, et al. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem. 2018;293(18): 6762-6775.
[29] WANG SW, SUN YM. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 2014;44(4): 1032-1040.
[30] KANESHIRO S, EBINA K, SHI K, et al. IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. J Bone Miner Metab. 2014;32(4):378-392.
[31] JOHNSON DE, O’KEEFE RA, GRANDIS JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234-248.
[32] PERUZZI B, CAPPARIELLO A, DEL FATTORE A, et al. c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling. Nat Commun. 2012;3:630.
[33] ZHENG Y, CHOW SO, BOERNERT K, et al. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways J Bone Miner Res. 2014; 29(9):1938-1949.
[34] SUDA T, TAKAHASHI N, UDAGAWA N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20(3):345-357.
[35] ZIMMERMANN A, HERCHER D, REGNER B, et al. Evaluation of BMP-2 Minicircle DNA for Enhanced Bone Engineering and Regeneration. Curr Gene Ther. 2020;20(1):55-63.
[36] HUANG RL, YUAN Y, TU J, et al. Exaggerated inflammatory environment decreases BMP-2/ACS-induced ectopic bone mass in a rat model: implications for clinical use of BMP-2. Osteoarthritis Cartilage. 2014;22(8):1186-1196.
[37] HUANG RL, SUN Y, HO CK, et al. IL-6 potentiates BMP-2-induced osteogenesis and adipogenesis via two different BMPR1A-mediated pathways. Cell Death Dis. 2018;9(2):144.
[38] BASTIDAS-CORAL AP, BAKKER AD, ZANDIEH-DOULABI B, et al. Cytokines TNF-α, IL-6, IL-17F, and IL-4 Differentially Affect Osteogenic Differentiation of Human Adipose Stem Cells. Stem Cells Int. 2016;2016:1318256.
[39] SCHELLER J, GARBERS C, ROSE-JOHN S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol. 2014; 26(1):2-12.
[40] MCGREGOR NE, MURAT M, ELANGO J, et al. IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signali ng promotes bone formation and osteoclastogenesis. J Biol Chem. 2019;294(19):7850-7863.
[41] KAUR S, BANSAL Y, KUMAR R, et al. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorg Med Chem. 2020;28(5):115327.
[42] JOHNSON RW, MCGREGOR NE, BRENNAN HJ, et al. Glycoprotein130 (Gp130)/interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone. Bone. 2015;81:343-351.
[43] UDAGAWA N, TAKAHASHI N, KATAGIRI T, et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med. 1995;182(5): 1461-1468.
[44] RAGIPOGLU D, DUDECK A, HAFFNER-LUNTZER M, et al. The Role of Mast Cells in Bone Metabolism and Bone Disorders. Front Immunol. 2020;11:163.
[45] AMARASEKARA DS, YUN H, KIM S, et al. Regulation of Osteoclast Differentiation by Cytokine Networks. Immune Netw. 2018;18(1):e8.
[46] AL-HUMIDAN A, RALSTON SH, HUGHES DE, et al. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res. 1991;6(1):3-8.
[47] FENG W, LIU H, LUO T, et al. Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-κB, ERK and JNK signaling pathways. Sci Rep. 2017;7:41411.
[48] QING H, DESROULEAUX R, ISRANI-WINGER K, et al. Origin and Function of Stress-Induced IL-6 in Murine Models. Cell. 2020;182(2):372-387.e14.
[49] KIM HJ, KIM HJ, CHOI Y, et al. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. Int J Mol Sci. 2019;20(6):1467.
[50] HADJI P, COLLI E, REGIDOR PA. Bone health in estrogen-free contraception. Osteoporos Int. 2019;30(12):2391-2400.
[51] ROODMAN GD, KURIHARA N, OHSAKI Y, et al. Interleukin 6. A potential autocrine/paracrine factor in Paget’s disease of bone]. J Clin Invest. 1992; 89(1):46-52.
[52] DEVLIN RD, REDDY SV, SAVINO R, et al. IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res. 1998;13(3):393-399.
[53] ZHANG D, HUANG Y, HUANG Z, et al. FTY-720P Suppresses Osteoclast Formation by Regulating Expression of Interleukin-6 (IL-6), Interleukin-4 (IL-4), and Matrix Metalloproteinase 2 (MMP-2). Med Sci Monit. 2016;22:2187-94.
[54] SIVARAJ KK, ADAMS RH. Blood vessel formation and function in bone. Development. 2016;143(15):2706-15.
[55] ZHA Y, LI Y, LIN T, et al. Progenitor cell-derived exosomes endowed with VEGF plasmids enhance osteogenic induction and vascular remodeling in large segmental bone defects. Theranostics. 2021;11(1):397-409.
[56] MAJIDINIA M, SADEGHPOUR A, YOUSEFI B. The roles of signaling pathways in bone repair and regeneration. J Cell Physiol. 2018;233(4):2937-2948.
[57] RAMAZANI Y, KNOPS N, ELMONEM MA, et al. Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biol. 2018;68-69:44-66.
[58] WANG Y, DANG Z, CUI W, et al. Mechanical stretch and hypoxia inducible factor-1 alpha affect the vascular endothelial growth factor and the connective tissue growth factor in cultured ACL fibroblasts. Connect Tissue Res. 2017;58(5):407-413.
[59] WANG WB, LI HP, YAN J, et al. CTGF regulates cyclic stretch-induced vascular smooth muscle cell proliferation via microRNA-19b-3p. Exp Cell Res. 2019; 376(1):77-85.
[60] RAMASAMY SK, KUSUMBE AP, SCHILLER M, et al. Blood flow controls bone vascular function and osteogenesis. Nat Commun. 2016;7:13601.
[61] CHEN Y, ZHAO B, ZHU Y, et al. HIF-1-VEGF-Notch mediates angiogenesis in temporomandibular joint osteoarthritis. Am J Transl Res. 2019;11(5):2969-2982.
[62] BAKSHI R, HOKUGO A, KHALIL D, et al. A Chemotactic Functional Scaffold with VEGF-Releasing Peptide Amphiphiles Facilitates Bone Regeneration by BMP-2 in a Large-Scale Rodent Cranial Defect Model. Plast Reconstr Surg. 2021;147(2):386-397.
[63] COUGHLIN BA, TROMBLEY BT, MOHR S. Interleukin-6 (IL-6) mediates protection against glucose toxicity in human Müller cells via activation of VEGF-A signaling. Biochem Biophys Res Commun. 2019;517(2):227-232.
[64] GAO Y, ZHANG Y, YAO Y, et al. Avian leukosis virus subgroup J induces VEGF expression via NF-κB/PI3K-dependent IL-6 production. Oncotarget. 2016;7(49):80275-80287.
[65] MARONE G, VARRICCHI G, LOFFREDO S, et al. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur J Pharmacol. 2016;778:146-151.
[66] GRABAUSKAS G, WU X, GAO J, et al. Prostaglandin E(2), Produced by Mast Cells in Colon Tissues From Patients With Irritable Bowel Syndrome, Contributes to Visceral Hypersensitivity in Mice. Gastroenterology. 2020; 158(8):2195-2207.e6.
[67] PARDANANI A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol. 2019;94(3):363-377.
[68] KOCH S, SOPEL N, FINOTTO S. Th9 and other IL-9-producing cells in allergic asthma. Semin Immunopathol. 2017;39(1):55-68.
[69] MCHALE C, MOHAMMED Z, DEPPEN J, et al. Interleukin-6 potentiates FcεRI-induced PGD(2) biosynthesis and induces VEGF from human in situ-matured skin mast cells. Biochim Biophys Acta Gen Subj. 2018;1862(5):1069-1078.
[70] KOMI DEA, REDEGELD FA. Role of Mast Cells in Shaping the Tumor Microenvironment. Clin Rev Allergy Immunol. 2020;58(3):313-325.
[71] ZHU M, YANG M, YANG Q, et al. Chronic Hypoxia-Induced Microvessel Proliferation and Basal Membrane Degradation in the Bone Marrow of Rats Regulated through the IL-6/JAK2/STAT3/MMP-9 Pathway. Biomed Res Int. 2020;2020:9204708.
[72] XIONG S, WANG R, CHEN Q, et al. Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling. Am J Cancer Res. 2018;8(2):302-316.
[73] EINHORN TA, GERSTENFELD LC. Fracture healing: mechanisms and interventions. Nat Rev Rheumatol. 2015;11(1):45-54.
[74] MA Y, ZHOU Y, WU F, et al. The Bidirectional Interactions Between Inflammation and Coagulation in Fracture Hematoma. Tissue Eng Part B Rev. 2019;25(1):46-54.
[75] WALTERS G, POUNTOS I, GIANNOUDIS PV. The cytokines and micro-environment of fracture haematoma: Current evidence. J Tissue Eng Regen Med. 2018;12(3):e1662-e1677.
[76] WANG C, QI B, ZHANG C, et al. Identification of key genes influenced by fixation stability in early fracture hematoma and elucidation of their roles in fracture healing. Exp Ther Med. 2017;14(5):4633-4638.
[77] WANG X, LUO Y, MASCI PP, et al. Influence of Interleukin-1 Beta on Platelet-Poor Plasma Clot Formation: A Potential Impact on Early Bone Healing. PLoS One. 2016;11(2):e0149775.
[78] LIM ZXH, RAI B, TAN TC, et al. Autologous bone marrow clot as an alternative to autograft for bone defect healing. Bone Joint Res. 2019;8(3):107-117.
[79] MIHALKO E, BROWN AC. Clot Structure and Implications for Bleeding and Thrombosis. Semin Thromb Hemost. 2020;6(1):96-104.
[80] WANG X, FRIIS TE, MASCI PP, et al. Alteration of blood clot structures by interleukin-1 beta in association with bone defects healing. Sci Rep. 2016;6: 35645.
[81] LUYENDYK JP, SCHOENECKER JG, FLICK MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019;133(6):511-520.
[82] GARCÍA X, SEYVE L, TELLIER Z, et al. Aggregates Dramatically Alter Fibrin Ultrastructure. Biophys J. 2020;118(1):172-181.
[83] WEISEL JW, LITVINOV RI. Fibrin Formation, Structure and Properties. Subcell Biochem. 2017;82:405-456.
[84] CRONJÉ HT, NIENABER-ROUSSEAU C, ZANDBERG L, et al. Fibrinogen and clot-related phenotypes determined by fibrinogen polymorphisms: Independent and IL-6-interactive associations. PLoS One. 2017;12(11):e0187712.
[85] NOORI A, ASHRAFI SJ, VAEZ-GHAEMI R, et al. A review of fibrin and fibrin composites for bone tissue engineering. Int J Nanomedicine. 2017;12:4937-4961.
[86] REIN-SMITH CM, ANDERSON NW, FARRELL DH. Differential regulation of fibrinogen γ chain splice isoforms by interleukin-6. Thromb Res. 2013; 131(1):89-93.
[87] SJØLAND JA, SIDELMANN JJ, BRABRAND M, et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost. 2007;98(2):339-345.
[88] Sahni A, Francis CW. Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2. J Thromb Haemost. 2003;1(6): 1271-1277.
|